Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KCNN4 | O15554 | 7/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylethylmalonamide SCHEMBL29755357 | 0.98 | MAPT (0.53) | MAPTKMT2AHTTKCNN4CYP2C19 | |
| Phenylethylmalonamide - SCHEMBL7828223 | 0.92 | KMT2A (0.52) | MAPTKMT2AHTTKCNN4CYP2C19 | |
| SCHEMBL15945879 | 0.84 | PIN1 (0.47) | MAPTKMT2AKCNN4CYP2D6CHRM2 | |
| SCHEMBL2291949 | 0.83 | CYP2C19 (0.47) | MAPTKMT2AHTTKCNN4CYP2C19 | |
| SCHEMBL29467999 | 0.82 | NPC1 (0.42) | MAPTKMT2AKIF11LMNACYP1A2 | |
| SCHEMBL21269854 | 0.81 | CYP2C19 (0.45) | MAPTKMT2AHTTKCNN4CYP2C19 | |
| SCHEMBL21268799 | 0.81 | CYP2C19 (0.45) | MAPTKMT2AHTTKCNN4CYP2C19 | |
| SCHEMBL21269982 | 0.81 | CYP2C19 (0.45) | MAPTKMT2AHTTKCNN4CYP2C19 | |
| SCHEMBL28875698 | 0.81 | CYP2C19 (0.45) | MAPTKMT2AHTTKCNN4CYP2C19 | |
| SCHEMBL28316424 | 0.81 | CYP2C19 (0.45) | MAPTKMT2AHTTKCNN4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1051 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122085568-A | Ion gel electrolyte composition capable of being subjected to room-temperature in-situ spontaneous polymerization, electrolyte and application | — | 2026-05-26 | — | — | CN | claimed |
| US-12630726-B2 | Manufacturing art paints from discarded materials | Encore Artistic Solutions, Inc | 2026-05-19 | — | — | US | claimed |
| US-12606723-B2 | Thermosetting resin composition, semiconductor device and electrical/electronic component | KYOCERA CORPORATION (JP) | 2026-04-21 | — | — | US | claimed |
| EP-3962413-B1 | A NEW ADVANCED FORMULATION FOR HYDROPHOBIC INTRAOCULAR LENSES AND THEIR PRODUCTION METHOD | VSY BIYOTEKNOLOJI VE ILAC SANAYI ANONIM SIRKETI (TR) | 2026-04-08 | — | — | EP | claimed |
| EP-4716528-A1 | PREPARATION OF TOLERIZING NANOPARTICLES FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS | Cour Pharmaceuticals Development Company Inc. (US) | 2026-04-01 | — | — | EP | claimed |
| EP-4687970-A1 | TOLERIZING IMMUNE MODIFYING NANOPARTICLES FOR MYASTHENIA GRAVIS TREATMENT | Cour Pharmaceuticals Development Company Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| US-20260028489-A1 | SUPPORTED POLYMERIZATION INHIBITORS AND THEIR USE IN CURABLE COMPOSITIONS FOR 3D PRINTING | ALIGN TECHNOLOGY INC (US) | 2026-01-29 | — | — | US | claimed |
| US-20260027276-A1 | APPARATUS FOR REMOVING CHEMOTHERAPY COMPOUNDS FROM BLOOD | DELCATH SYSTEMS, INC. (US) | 2026-01-29 | — | — | US | claimed |
| EP-4674873-A1 | CYCLIC OLIGOMER, METHOD FOR PRODUCING SAME, COMPOUNDING MATERIAL AND COMPOSITE MATERIAL COMPRISING SAME, AND MEDICAL ARTICLE SURFACE-MODIFIED OR SURFACE-TREATED THEREWITH | Korea Institute of Science and Technology (KR) | 2026-01-07 | — | — | EP | claimed |
| WO-2025198684-A9 | BaTiO3 NANOCRYSTALS AND NANOCOMPOSITES | PIXELLIGENT TECHNOLOGIES LLC (US) | 2025-11-27 | — | — | WO | claimed |
| US-20060251649-A1 | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2006-11-09 | — | — | US | claimed |
| EP-1718971-A2 | SYSTEM AND METHOD FOR REAL-TIME DIAGNOSIS, TREATMENT, AND THERAPEUTIC DRUG MONITORING | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2006-11-08 | — | — | EP | claimed |
| WO-2005098429-A2 | SYSTEM AND METHOD FOR REAL-TIME DIAGNOSIS, TREATMENT, AND THERAPEUTIC DRUG MONITORING | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2005-10-20 | — | — | WO | claimed |
| US-20050233459-A1 | Marker detection method and apparatus to monitor drug compliance | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2005-10-20 | — | — | US | claimed |
| US-20050054942-A1 | System and method for therapeutic drug monitoring | UNIVERSITY OF FLORIDA | 2005-03-10 | — | — | US | claimed |
| US-6010715-A | SUSTAINED DRUG RELEASE; MONOLITHIC CARRIER | BERTEK, INC. (US) | 2000-01-04 | — | — | US | claimed |
| EP-0563507-B1 | Transdermal patch incorporating a polymer film incorporated with an active agent | BERTEK INC (US) | 1998-05-27 | — | — | EP | claimed |
| US-5679373-A | MELT-BLENDING THERMOPLASTIC MATRIX; IMPERMEABLE BACKING; LAMINATION WITHOUT ADHESIVE; CONTROLLED RELEASE | BERTEK, INC. (US) | 1997-10-21 | — | — | US | claimed |
| US-5662926-A | SOLVENT FREE | BERTEK, INC. (US) | 1997-09-02 | — | — | US | claimed |
| EP-0563507-A1 | Transdermal patch incorporating a polymer film incorporated with an active agent | MLI ACQUISITION CORP. II (US) | 1993-10-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630726-B2 | Manufacturing art paints from discarded materials | PKM, KMT5B, SETDB1 | MAPT 41/4885KMT2A 62/4885HTT 688/4885 |
| US-20260027276-A1 | APPARATUS FOR REMOVING CHEMOTHERAPY COMPOUNDS FROM BLOOD | HCCS, F8, ABCC1 | MAPT 3806/4885KMT2A 2157/4885HTT 4045/4885 |
| US-20060251649-A1 | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate | GRM2, GRIN2C, GRIN2A | MAPT 2325/4885KMT2A 157/4885HTT 3797/4885 |
| US-12606723-B2 | Thermosetting resin composition, semiconductor device and electrical/electronic component | RPS3A, SEM1, DAP3 | MAPT 333/4885KMT2A 1835/4885HTT 1550/4885 |
| US-20260028489-A1 | SUPPORTED POLYMERIZATION INHIBITORS AND THEIR USE IN CURABLE COMPOSITIONS FOR 3D PRINTING | ILK, MTCL3, MARK3 | MAPT 100/4885KMT2A 564/4885HTT 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.